JaLCDOI 10.18926/AMO/40132
FullText URL 64_4_243.pdf
Author Myo-Khin| Myat-Tin-Htwe-Kyaw| Yi-Yi-Kyaw| Ohmar-Lwin| Myat-Phone-Kyaw| Khin-May-Oo| Shimono, Kunio| Koide, Norio| Okada, Shigeru|
Abstract The efficacy of AntiOxidant Biofactor (AOB(R)) for the management of apparently healthy subjects with chronic hepatitis C infection was investigated. A total of 60 subjects (35 males, 25 females) participated in the trial. AOB was given orally in 2 packs (3g per pack) 3 times per day. 17 subjects had taken AOB for 3 years, 31 subjects up to 2 years, and 41 subjects up to one year. The initial mean (SD) serum alamine aminotransferase (ALT) level was 46.3+/-35.4IU/L, and significant (p0.05, paired t-test) reductions in the mean serum ALT levels were observed at 6 months (38.6+/-21.5IU/L), 18 months (31.9+/-18.1IU/L), 2 years (31.2+/-14.6IU/L), and 3 years (28.0+/-15.9IU/L). Those presenting with high serum ALT levels (30 subjects) demonstrated significant levels (p0.05, paired t-test) of reduction in the mean serum ALT levels at 6, 12, 18, 24, and 36 months of treatment. No side effects were observed and the AOB treatment was well tolerated by all subjects.
Keywords hepatitis C AntiOxidant Biofactor (AOB®) ALT level
Amo Type Original Article
Published Date 2010-08
Publication Title Acta Medica Okayama
Volume volume64
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 248
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 20802541
Web of Science KeyUT 000281384400005